title: Melanomas and melanoma cell lines do not express HLA-G, and the expression cannot be induced by gammaIFN treatment.
abstract: HLA-G is an effective ligand of natural killer (NK) inhibitory receptors, HLA-G transcripts have been detected in several human tumors, and cytokines like gamma interferon (IFN) enable HLA-G molecules to be expressed. These findings are particularly upsetting in case of melanomas: IFN treatment is frequently included in melanoma therapeutic protocols, and downregulation of classical class I molecules occurs in nearly half of these tumors. Therefore, a melanoma cell downregulating classical class I and de novo expressing HLA-G, either constitutively or upon IFN treatment, is probably a stealthy target for the immune system, having inhibited both the cytotoxic T lymphocyte (CTL) and the NK activity. To elucidate this point we have investigated the expression of HLA-G molecules in 45 melanoma cell lines before and after gammaIFN treatment. Analysis was performed by immunofluorescence and flow cytometry, using the anti-HLA-G MoAbs 87G and G233, by Western blot, using the anti-HLA-G MEM/G1 MoAb and PAG1 antiserum, and by RT-PCR analysis. In addition, 8 melanoma tissues from patients free from therapy and 6 nevi were studied by immunohistochemistry using the 87G MoAb. No evidence was gathered of HLA-G expression, neither constitutive nor, in cell lines, after gammaIFN treatment. We therefore conclude that HLA-G expression is an uncommon event in melanomas, and that a therapy including IFNs cannot harm the patient by inducing the de novo expression of HLA-G molecules at least in its G1 isoform.
authors.affiliation: Laboratory of Immunogenetics, IST National Institute for Cancer Research, Genoa, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Frumento
authors.forename: S
authors.initials: S
authors.lastname: Franchello
authors.forename: G L
authors.initials: GL
authors.lastname: Palmisano
authors.forename: M R
authors.initials: MR
authors.lastname: Nicotra
authors.forename: P
authors.initials: P
authors.lastname: Giacomini
authors.forename: Y W
authors.initials: YW
authors.lastname: Loke
authors.forename: D E
authors.initials: DE
authors.lastname: Geraghty
authors.forename: M
authors.initials: M
authors.lastname: Maio
authors.forename: C
authors.initials: C
authors.lastname: Manzo
authors.forename: P G
authors.initials: PG
authors.lastname: Natali
authors.forename: G B
authors.initials: GB
authors.lastname: Ferrara
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology; D015153:Blotting, Western; D005434:Flow Cytometry; D006680:HLA Antigens / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D059951:HLA-G Antigens; D015395:Histocompatibility Antigens Class I / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D007371:Interferon-gamma / Q000494:pharmacology*; D008545:Melanoma / Q000276:immunology*; D012333:RNA, Messenger / Q000032:analysis; D014407:Tumor Cells, Cultured
chemical_list: D000911:Antibodies, Monoclonal; D006680:HLA Antigens; D059951:HLA-G Antigens; D015395:Histocompatibility Antigens Class I; D012333:RNA, Messenger; D007371:Interferon-gamma